Literature DB >> 1659305

Pharmacodynamics of daptomycin and vancomycin on Enterococcus faecalis and Staphylococcus aureus demonstrated by studies of initial killing and postantibiotic effect and influence of Ca2+ and albumin on these drugs.

H Hanberger1, L E Nilsson, R Maller, B Isaksson.   

Abstract

The pharmacodynamics of daptomycin and vancomycin on Enterococcus faecalis ATCC 29212 and Staphylococcus aureus ATCC 25923 were investigated by studying the postantibiotic effect (PAE) and initial killing. The influence of Ca2+ and albumin on these drugs was also evaluated. The PAE was studied by use of bioluminescence assay of bacterial ATP. Daptomycin at clinically achievable concentrations produced a dose-dependent PAE on E. faecalis (0.6 to 6.7 h) and S. aureus (1.0 to 6.3 h). The long PAE of daptomycin was seen simultaneously with a potent dose-dependent initial killing assayed by viable count determination. The initial change in bacterial ATP was not as extensive as the decrease in viability. Vancomycin at corresponding concentrations produced shorter PAEs on E. faecalis (0.5 to 1.0 h) and S. aureus (1.3 to 1.8 h). This coincides with a weak non-dose-dependent initial change in viability and intracellular ATP. The MICs of vancomycin were not influenced by different Ca2+ concentrations or by the addition of albumin to the broth. The MICs of daptomycin for both strains were lowered, and the PAEs were prolonged with increasing concentrations of Ca2+ in the broth. The PAE of daptomycin was Ca2+ dependent to the same extent as the MIC was. In the presence of physiological concentrations of albumin and free Ca2+, the PAEs of daptomycin on both strains were reduced and the MICs were increased in comparison with the results obtained in pure Mueller-Hinton broth with approximately the same free Ca2+ concentration. This decrease in daptomycin activity was considered to be due to the albumin binding of daptomycin. Despite the albumin binding of daptomycin, the PAE produced on E. faecalis and S. aureus in the presence of a physiological free Ca2+ concentration was still over 6 h at clinically achievable concentrations.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1659305      PMCID: PMC245255          DOI: 10.1128/AAC.35.9.1710

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  21 in total

1.  Bactericidal activity of deptomycin (LY146032) compared with those of ciprofloxacin, vancomycin, and ampicillin against enterococci as determined by kill-kinetic studies.

Authors:  C W Stratton; C Liu; H B Ratner; L S Weeks
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

2.  The effect of cultural conditions on the activity of LY146032 against staphylococci and streptococci.

Authors:  J H Andrew; M C Wale; L J Wale; D Greenwood
Journal:  J Antimicrob Chemother       Date:  1987-08       Impact factor: 5.790

3.  Comparative in-vitro activity of LY146032 a new peptolide, with vancomycin and eight other agents against gram-positive organisms.

Authors:  C A Benson; F Beaudette; G Trenholm
Journal:  J Antimicrob Chemother       Date:  1987-08       Impact factor: 5.790

4.  In vitro activity of LY146032 against staphylococci, streptococci, and enterococci.

Authors:  R J Fass; V L Helsel
Journal:  Antimicrob Agents Chemother       Date:  1986-11       Impact factor: 5.191

5.  Postantibiotic and bactericidal effect of imipenem against Pseudomonas aeruginosa.

Authors:  I Odenholt; B Isaksson; L Nilsson; O Cars
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-02       Impact factor: 3.267

6.  ATP-linked calcium transport in cells and membrane vesicles of Streptococcus faecalis.

Authors:  H Kobayashi; J Van Brunt; F M Harold
Journal:  J Biol Chem       Date:  1978-04-10       Impact factor: 5.157

7.  In vitro activity and mechanism of action of A21978C1, a novel cyclic lipopeptide antibiotic.

Authors:  G M Eliopoulos; C Thauvin; B Gerson; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1985-03       Impact factor: 5.191

8.  Daptomycin (LY146032) treatment of experimental enterococcal endocarditis.

Authors:  L M Bush; J A Boscia; D Kaye
Journal:  Antimicrob Agents Chemother       Date:  1988-06       Impact factor: 5.191

9.  Single-dose kinetics of intravenous vancomycin.

Authors:  D J Krogstad; R C Moellering; D J Greenblatt
Journal:  J Clin Pharmacol       Date:  1980-04       Impact factor: 3.126

10.  In vitro activity of LY146032 against gram-positive bacteria.

Authors:  M Silva; N V Jacobus; S L Gorbach
Journal:  Diagn Microbiol Infect Dis       Date:  1988-02       Impact factor: 2.803

View more
  40 in total

1.  Resistance studies with daptomycin.

Authors:  J A Silverman; N Oliver; T Andrew; T Li
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

2.  Population pharmacokinetics of daptomycin.

Authors:  Barry Dvorchik; Robert D Arbeit; Julia Chung; Susan Liu; William Knebel; Helen Kastrissios
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

3.  Short-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations.

Authors:  Brian T Tsuji; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

4.  Functional relationship between bacterial cell density and the efficacy of antibiotics.

Authors:  Klas I Udekwu; Nicholas Parrish; Peter Ankomah; Fernando Baquero; Bruce R Levin
Journal:  J Antimicrob Chemother       Date:  2009-02-13       Impact factor: 5.790

5.  Activity of serum concentrations of daptomycin vs. vancomycin against vancomycin-susceptible and resistant Enterococcus faecium in the presence of albumin physiological concentrations: an in vitro pharmacodynamic simulation.

Authors:  L Alou; L Aguilar; M J Giménez; M Torrico; D Sevillano
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-05-21       Impact factor: 3.267

6.  In vitro activities of daptomycin, vancomycin, and penicillin against Clostridium difficile, C. perfringens, Finegoldia magna, and Propionibacterium acnes.

Authors:  Kerin L Tyrrell; Diane M Citron; Yumi A Warren; Helen T Fernandez; C Vreni Merriam; Ellie J C Goldstein
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

7.  Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations.

Authors:  R L Akins; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

8.  Activity of daptomycin with or without 25 percent ethanol compared to combinations of minocycline, EDTA, and 25 percent ethanol against methicillin-resistant Staphylococcus aureus isolates embedded in biofilm.

Authors:  R Estes; J Theusch; A Beck; D Pitrak; Kathleen M Mullane
Journal:  Antimicrob Agents Chemother       Date:  2013-02-12       Impact factor: 5.191

9.  Daptomycin or teicoplanin in combination with gentamicin for treatment of experimental endocarditis due to a highly glycopeptide-resistant isolate of Enterococcus faecium.

Authors:  F Caron; M D Kitzis; L Gutmann; A C Cremieux; B Maziere; J M Vallois; A Saleh-Mghir; J F Lemeland; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

10.  In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin.

Authors:  K C Lamp; M J Rybak; E M Bailey; G W Kaatz
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.